Drug intelligence / Profile preview

IMC-201

Development stage: Preclinical
Lead developer: ImmuneOncia Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics

Overview

IMC-201 is a bispecific antibody developed by ImmuneOncia Therapeutics for the treatment of cancer. It targets both CD47 and PD-L1 (programmed death-ligand 1), functioning as an immunomodulatory agent. By inhibiting CD47—a "don't eat me" signal on tumor cells—and PD-L1—an immune checkpoint that suppresses T-cell activity—IMC-201 aims to enhance anti-tumor immune responses through both innate and adaptive immunity. The drug is currently in preclinical development for neoplasms (cancer)[1][2][4].

Targets

CD47 (Cluster of Differentiation 47)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on IMC-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-201.

Explore the full profile